SEC Form 4 · accession 0001209191-17-041195
ImmunityBio, Inc. · IBRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John C Thomas
Director
Period of report
Jun 20, 2017
Accepted (ET)
Jun 21, 2017 · 4:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001326110
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 20, 2017 | S | 10,000 | $7.43 | D | 308,655 | D | |
| Common Stock | Jun 20, 2017 | S | 20,000 | $7.44 | D | 288,655 | D | |
| Common Stock | Jun 20, 2017 | S | 10,000 | $7.54 | D | 278,655 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 6, 2016.